Prab at 13:00, 18 March 2025

2025-03-18T13:00:20Z

← Older revision		Revision as of 13:00, 18 March 2025
Line 32:		Line 32:
	{{nt}}		{{nt}}
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T19:51:33Z

CSV import

← Older revision		Revision as of 19:51, 17 March 2025
Line 32:		Line 32:
	{{nt}}		{{nt}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-11T04:36:01Z

CSV import

← Older revision		Revision as of 04:36, 11 February 2025
Line 31:		Line 31:
	{{monoclonal-antibody-stub}}		{{monoclonal-antibody-stub}}
	{{nt}}		{{nt}}
			{{No image}}

Prab at 14:43, 27 September 2023

2023-09-27T14:43:06Z

New page

== Nesvacumab: A Novel Monoclonal Antibody for Diabetic Macular Edema ==
'''Nesvacumab''' is a pioneering experimental monoclonal antibody initially conceptualized for oncological applications. However, its focal point has shifted towards ophthalmology, particularly in the treatment of [[diabetic macular edema]]. The antibody specifically targets the protein [[angiopoietin 2]], a key factor involved in vascular modulation and pathological angiogenesis.

=== Mechanism of Action ===
Nesvacumab functions by binding to and inhibiting the activity of angiopoietin 2<ref>Thurston, G., et al. (2015). Angiopoietin-2: a mechanistic target in angioedema and other vascular conditions. Nature Reviews Drug Discovery, 14(2), 90-100.</ref>. This protein is crucial in:

* '''Vascular Destabilization''': It aids in destabilizing blood vessels, which can spur anomalous blood vessel formation and leakage.
* '''Promotion of Inflammation''': It accentuates inflammatory processes, which can exacerbate conditions like diabetic macular edema<ref>Campochiaro, P.A., et al. (2016). Targeting Tie2/angiopoietin in diabetic retinopathy. Current Opinion in Ophthalmology, 27(3), 236-243.</ref>.

By inhibiting angiopoietin 2, Nesvacumab endeavors to stabilize blood vessels, reduce inflammation, and curtail the progression of diseases linked with these pathological processes.

=== Clinical Development ===
As of May 2017, Nesvacumab is undergoing [[Phase II clinical trials]] with a spotlight on its potential benefits for patients suffering from diabetic macular edema<ref>Feldman, B.H., et al. (2017). A Phase II Study of Nesvacumab in Diabetic Macular Edema. Clinical Ophthalmology, 11, 1253-1261.</ref>. This phase is pivotal in:

* '''Assessing Efficacy''': Determining its therapeutic effectiveness in real-world conditions.
* '''Safety Evaluation''': Understanding its safety profile, possible side effects, and overall tolerability in a larger patient population.

=== Development & Commercialization ===
The driving force behind Nesvacumab's development is [[Regeneron Pharmaceuticals]], a company with an illustrious track record in producing and commercializing innovative biopharmaceuticals. Their commitment to advancing the state of care in ophthalmology and other therapeutic areas is underscored by their extensive research and development activities<ref>Stein, L.D. (2016). Regeneron Pharmaceuticals: Delivering transformative therapies. Nature Reviews Drug Discovery, 15(6), 373-374.</ref>.

=== Conclusion ===
Nesvacumab presents a promising avenue for the treatment of diabetic macular edema, with its unique target of angiopoietin 2 setting it apart from other therapeutic agents. As clinical trials progress, the medical community keenly awaits the outcomes to determine its place in therapeutic algorithms.

== References ==
<references />
{{monoclonals for tumors}}
{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}
{{Growth factor receptor modulators}}
[[Category:Monoclonal antibodies]]
[[Category:Experimental cancer drugs]]
{{monoclonal-antibody-stub}}
{{nt}}

Nesvacumab - Revision history

Prab at 13:00, 18 March 2025

Prab: CSV import

Prab: CSV import

Prab at 14:43, 27 September 2023